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Introduction: Pemetrexed is an S-phase targeted drug in front-line 
or maintenance therapy of advanced nonsquamous non–small-cell 
lung cancer (NSCLC) but methods are needed for predicting the 
drug response. Dexamethasone is typically administered the day 
before, the day of, and the day after pemetrexed. As dexamethasone 
strongly regulates many genes including p53 through the glucocorti-
coid receptor (GR), we hypothesized that dexamethasone influences 
tumor response to pemetrexed.
Methods: Eight nonsquamous NSCLC cell line models with var-
ied p53 and GRα/GRβ status were used for gene expression and 
 cell-cycle analyses and for loss- or gain-of-function experiments.
Results: In three cell lines dexamethasone profoundly, but revers-
ibly, suppressed the fraction of S-phase cells. Dexamethasone also 
reversibly repressed expression of thymidylate synthase and dihy-
drofolate reductase, which are primary targets of pemetrexed but 
are also quintessential S-phase enzymes as well as the S-phase–
dependent expression of thymidine kinase 1. Dexamethasone also 
decreased expression of the major pemetrexed transporters, the 
reduced folate carrier and the proton coupled folate transporter. 
Only cells expressing relatively high GRα showed these dexameth-
asone effects, regardless of p53 status. In cells expressing low GRα, 
the dexamethasone response was rescued by ectopic GRα. Further, 
depletion of p53 did not attenuate the dexamethasone effects. 
The presence of dexamethasone during pemetrexed treatment pro-
tected against pemetrexed cytotoxicity in only the dexamethasone 
responsive cells.
Conclusions: The results predict that in nonsquamous NSCLC 
tumors, reversible S-phase suppression by dexamethasone, possi-
bly combined with a reduction in the drug transporters, attenuates 
responsiveness to pemetrexed and that GR status is a principal deter-
minant of tumor variability of this response.
Key Words: Non–small-cell lung cancer, Pemetrexed, p53, 
Glucocorticoid receptor.
(J Thorac Oncol. 2014;9: 519–526)
Non–small-cell lung cancer (NSCLC) comprises 85% of all lung cancer cases and the majority of those patients 
have regional or systemic metastases. Therefore systemic che-
motherapy forms an important component of the management 
of NSCLC. The efficacy of various chemotherapeutic agents 
used for the treatment of NSCLC was, for many years, similar 
among the different histologic subtypes. Randomized clini-
cal trials have now shown that the efficacy of pemetrexed is 
superior to that of other chemotherapy drugs in nonsquamous 
NSCLC and inferior to that of other drugs in squamous cell 
lung cancer when given as monotherapy or in combination 
with a platinum compound.1–4 Pemetrexed has now received 
approval by regulatory agencies in the United States and in 
Europe for nonsquamous NSCLC patients for front-line 
therapy in advanced-stage disease in combination with cis-
platin, as maintenance therapy after front-line therapy, and in 
patients with recurrent disease. On the basis of these data and 
in consideration of its limited toxicity profile, pemetrexed has 
become the preferred chemotherapy drug in the management 
of nonsquamous NSCLC.
Despite its widespread use, the efficacy of peme-
trexed in advanced-stage NSCLC is modest, with a median 
 progression-free survival of 5.5 months in the front-line setting 
when combined with cisplatin and only 3.5 months as single 
agent in patients with recurrent nonsquamous NSCLC. These 
data suggest that the clinical benefit from pemetrexed is quite 
variable even among patients with nonsquamous NSCLC, 
highlighting the need to identify predictors of clinical ben-
efit from pemetrexed. Such predictors would enable treatment 
decisions that would greatly benefit individual patients while 
avoiding extended chemotherapies that are ineffective.
Pemetrexed is transported into the cell through two 
pharmacologically relevant principal membrane transport-
ers, the reduced folate carrier (RFC) and the proton coupled 
folate transporter (PCFT).5 Polyglutamation of pemetrexed 
by  folyl-polyglutamate synthase (FPGS) results in increased 
cellular retention of the drug and increases its affinity for 
some of its target enzymes.6 Pemetrexed inhibits nucleotide 
biosynthesis principally by inhibiting thymidylate synthase 
(TS) but at pharmacologic doses it is also an inhibitor of 
dihydrofolate reductase (DHFR), glycinamide ribonucleotide 
 formyltransferase (GARFT), and 5-aminoimidazole-4-car-
boxamide ribonucleotide formyltransferase (AICARFT).7 It 
is generally accepted that TS inhibition causes cytotoxicity 
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via deprivation of deoxythymidine monophosphate (dTMP) 
needed for DNA synthesis and the associated “thymineless 
death”8 and also via elevation of deoxyuridine monophos-
phate (dUMP) and its misincorporation into DNA.9 Clearance 
of pemetrexed through the kidneys is rapid, resulting in a sys-
temic half-life of only 3.5 hours, with up to 90% of the drug 
being eliminated in the urine within 24 hours.10 The multitar-
geted action of pemetrexed, together with its prolonged cellu-
lar retention because of its relatively higher affinity for FPGS 
results in greater antitumor activity compared with older-gen-
eration antifolate drugs such as methotrexate.
The synthetic glucocorticoid dexamethasone (Dex) 
is used in standard practice as a concomitant medication 
during treatment with pemetrexed. Dex is typically dosed 
at 4 mg twice daily the day before, the day of, and the day 
after therapy with pemetrexed. An important role of Dex 
is to reduce the possibility of severe skin rash caused by 
pemetrexed. Dex is also included for its antiemetic proper-
ties particularly when pemetrexed is combined with cispla-
tin or carboplatin. The pharmacological actions of Dex are 
mediated by the glucocorticoid receptor (GR), which prin-
cipally acts as a transcription factor.11 Glucocorticoids regu-
late cell proliferation and apoptosis as well as inflammation 
and immune response.12 The nature of the physiological 
response as well as sensitivity to synthetic glucocorticoids 
such as Dex is tissue-dependent and variable. This variabil-
ity occurs among different individuals as well as among dif-
ferent tissues in the same individual.13
A single GR gene generates two major splice vari-
ants, GRα and GRβ; each isoform has variants that result 
from multiple translation start sites within their mRNAs.13 
Although GRβ only diverges from GRα by substitution of 
the carboxyl-terminal 50 amino acids in GRα by a nonho-
mologous 15 amino acid sequence, GRβ is unable to bind GR 
ligands.14 GRβ heterodimerizes with GRα to exert a domi-
nant negative effect on the transcriptional activity of GRα.14 
Therefore, the degree of Dex sensitivity of a tissue may be 
related to the functional GR status, determined by the level of 
GR expression as well as the ratio of GRα to GRβ. Whereas 
GRα is expressed ubiquitously, GRβ expression is potentially 
also significant in the present study of lung cancer because 
the limited types of tissues expressing this isoform include 
epithelial cells of the terminal bronchioles.14
Given the profound tissue-specific effects of Dex, its 
ability to regulate many genes, and its reported ability to 
modulate cellular senescence in lung cancer cells,15 it was 
of interest to examine the possibility that Dex may act on 
NSCLC cells to influence their responsiveness to pemetrexed. 
Immunohistochemical analysis of clinical NSCLC tumors 
shows considerable heterogeneity in total GR expression with 
relatively high total GR observed in approximately half of 
the tumors.16 Further, approximately 33% of lung adenocar-
cinomas harbor p53 mutations,17 and the p53 gene is a known 
target for activation by Dex.18 It was therefore of interest to 
explore both the GR status and the p53 status (wild-type (wt) 
p53, p53 deletions, or p53 mutations) of NSCLC cells as 
possible determinants of responsiveness to Dex, particularly 
molecular and cellular effects of Dex that could influence the 
action of pemetrexed.
MATERIALS AND METHODS
Cell Culture and Reagents
The nonsquamous NSCLC cell lines A549, H1299, H358, 
H226, H460, H1650, ADLC-5M2, and H292 were grown in 
Roswell Park Memorial Institute 1640 medium supplemented 
with 10% fetal bovine serum (FBS; Gibco; Life Technologies, 
Carlsbad, CA), 100 units/ml penicillin, 100 μg/ml streptomy-
cin, and 2 mM glutamine. The origin, growth conditions, and 
responsiveness to selected agents of the NSCLC cell lines used 
in this study have been previously described.19 All cell lines had 
been authenticated by single-nucleotide polymorphism (SNP) 
profiling within less than 12 months of in vitro propagation. The 
3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide 
(MTT) assay reagents were from MP Biomedicals (Solon, OH). 
Charcoal-stripped FBS was from Life Technologies (Carlsbad, 
CA). Dexamethasone was purchased from EMD Millipore 
(Billerica, MA). Dimethyl sulfoxide and crystal violet were pur-
chased from Fisher Scientific (Pittsburgh, PA). Propidium iodide/
RNase solution was purchased from BD Biosciences (San Jose, 
CA). Polymerase chain reaction (PCR) primers and TaqMan 
probes were either purchased from the Life Technologies inven-
tory or custom synthesized by Integrated DNA Technologies 
(Coralville, IA). The GRα-expressing lentivirus was from 
GenTarget Inc. (San Diego, CA). p53shRNA expressing lenti-
virus was a kind gift from Dr. Yubin Ge at Karmanos Cancer 
Institute. Blasticidin and puromycin were from Life Technogies 
and Sigma-Aldrich (St. Louis, MO). Anti-DHFR antibody (sc-
14778) was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA) and anti-TS antibody (# 9045) was purchased from 
Cell Signaling Technology (Danvers, MA).
Measurement of Gene Expression
To measure gene expression, mRNA was quantified by 
real-time reverse transcription (RT) PCR. Total RNA from 
cells was isolated using RNeasy minikit (Qiagen, Georgetown, 
MD) according to the manufacturer’s protocol. RT was per-
formed using 500 ng of total RNA and High-Capacity cDNA 
Archive kit (Life Technologies) according to the vendor’s 
protocol. cDNA was measured by quantitative real-time 
PCR using the StepOnePlus Real-Time PCR System (Life 
Technologies) and TaqMan Fast Universal PCR Master Mix 
(Life Technologies). All the mRNA measurements were car-
ried out using biological triplicate samples and C
T
 values were 
normalized to those of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). The mRNA levels are represented as RQ 
(relative quantification), which is calculated using the formula 
RQ = 2−ΔΔC
T
, where ΔΔC
T
 = ΔC
T
 sample − ΔC
T
 calibrator 
(ΔC
T
 = C
T
 of gene of interest − C
T
 of GAPDH).
Western Blot Analysis
Cell lysates were generated using radioimmunoprecipita-
tion assay (RIPA) buffer (150 mM NaCl, 1% nonyl phenoxy-
polyethoxylethanol (NP-40), 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 50 mM Tris of pH 8.0) contain-
ing protease inhibitor cocktail (Pierce Biotechnology, Thermo 
Fisher Scientific, Rockford, IL) and incubated on ice for 1 hour. 
Total protein concentration was determined by Bradford assay 
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 (Bio-Rad Laboratories, Hercules, CA). Protein samples (20 
μg) were resolved by electrophoresis on 8% sodium dodecyl 
sulfate–polyacrylamide gels and electrophoretically transferred 
to polyvinylidene difluoride (PVDF) membranes (Millipore 
Corporation, Bedford, MA) for 1 hour at 100 mV. The blots 
were probed with the appropriate primary antibody and the 
appropriate horseradish peroxidase conjugated secondary anti-
body. The protein bands were visualized using enhanced chemi-
luminescence reagents (Hyglo Quick Spray; Denville Scientific, 
Metuchen, NJ) following the vendor’s instructions.
Cell-Proliferation Assay
Cells (2000 per well) were seeded in 96-well plates in phe-
nol-red-free medium supplemented with charcoal-stripped FBS. 
Treatments were initiated after the cells were attached. At the 
appropriate time points, cell viability was determined by MTT 
assay; 10 μl of MTT (5mg/ml in phosphate-buffered saline) was 
added to each well followed by incubation at 37°C for 2 hours. The 
formazan crystal sediments were dissolved in 100 μl of dimethyl 
sulfoxide and absorbance was measured at 570 nm using the 
BioTek Synergy 2 Microplate Reader (BioTek, Winooski, VT). 
Each treatment was performed in six replicate wells.
Colony-Formation Assay
Cells were trypsinized and 2000, 1000, and 500 cells per 
well were plated in duplicate 6-well plates in phenol-red-free 
medium supplemented with charcoal-stripped FBS. Colonies 
were formed after 6 days. The cells were fixed with ice-cold 
methanol and stained with crystal violet. Images were obtained 
using the Oxford Optronix GelCount colony counter (Oxford 
Optronix Ltd., Abingdon, United Kingdom) and colonies 
were counted using the Oxford Optronix GelCount Software 
Version 1.1.2.0. The colony-formation assays were repeated at 
least three times and concordant results were obtained.
Cell-Cycle Analysis
Cells were trypsinized and harvested in phenol-red-
free medium supplemented with charcoal-stripped FBS. 
Cells (1 × 106) were washed and suspended in 500 μl of 
 phosphate-buffered saline. The cells were fixed with ice-cold 
100% ethanol added dropwise with constant agitation and 
incubated on ice for 20 minutes. The cell pellet was obtained 
by centrifugation and suspended in 500 μl of propidium iodide/
RNase solution and incubated in the dark at room temperature 
for 20 minutes. Cell-cycle distribution was determined using 
the BD LSR II analyzer (BD Biosciences) at the Microscopy, 
Imaging and Cytometry Resources Core at Karmanos Cancer 
Institute. The data were analyzed using ModFit software.
Gene Transduction and Selection 
of Recombinant Cells
To generate recombinant cells overexpressing GRα, 
cells were plated in a 24-well plate to 75% confluence and 
transduced with 50-μl lentivirus. Seventy-two hours later, blas-
ticidin (4 μg/ml or 6 μg/ml) was added to the cells. The cells 
were treated with blasticidin for 72 hours and then subcultured 
in complete media. Blasticidin was added to the media at every 
third passage of the subculture. The recombinant cells express-
ing p53 shRNA were generated by an identical procedure 
except that the antibiotic used for selection was puromycin.
Statistical Analysis
Statistical significance was determined using one way 
analysis of variance. The error bars in all graphs represent 
standard deviation of the mean. The p values are indicated in 
the figure legends.
RESULTS
Effect of Dex on the Expression of Genes 
Involved in Pemetrexed Action
As Dex is known to regulate the transcription of many 
genes through GR, we tested its effect on the expression of 
genes whose products have direct roles in the action of peme-
trexed. For this purpose, we first chose two commonly used 
lung adenocarcinoma cell line models, A549 and H1299. The 
cells were plated in hormone-depleted media and then treated 
with Dex (100 nM) for 48 hours. This concentration of Dex was 
chosen because it is the highest plasma concentration of Dex 
when humans are administered a single dose of 4 mg of Dex.20 
Gene expression was quantified by real-time RT-PCR. As seen 
in Figure 1A, in A549 cells, Dex suppressed the expression of 
TS and DHFR by 75% and also the expression of RFC (by 
45%) and PCFT (by 60%). The expression levels of GARFT, 
AICARFT, and FPGS were unaltered by Dex. In contrast, Dex 
did not significantly influence the expression of any of the genes 
tested in H1299 cells (Fig. 1B). Western blots confirmed that 
both TS and DHFR were downregulated by Dex at the protein 
level in A549 cells (Fig.1C) but their expression was unaffected 
in H1299 cells (Fig. 1D). The experiments were extended to 
additional lung cancer cell lines and they exhibited both sen-
sitivity (H292 and H226 cells) and insensitivity (H460, H358, 
ADLC-5M2, and H1650 cells) to Dex (Table 1). The Dex 
sensitivity of lung cancer cell line models was thus variable 
with respect to the regulation of the genes whose products are 
directly involved in mediating the cytotoxicity of pemetrexed.
Effect of Dex on Cell-Cycle Progression
As TS and DHFR are essential S-phase enzymes, we also 
tested the effect of Dex on thymidine kinase 1 (TK1), another 
S-phase–dependent enzyme. TK1 was also decreased by Dex in 
A549 cells but not in H1299 cells (Fig. 1A, B). Hence, it was 
of interest to test the effect of Dex on cell-cycle phase distribu-
tion in the lung cancer cell lines. Treatment with Dex caused a 
striking suppression of S-phase in A549 cells (Fig. 2A) but did 
not significantly alter the cell-cycle phase distribution in H1299 
cells (Fig. 2B). Thus, the differential sensitivity of A549 and 
H1299 cells to transcriptional regulation by Dex noted above 
is associated with the differential ability of Dex to suppress the 
S-phase fraction of cells. This association also extended to the 
other NSCLC cell line models (Table 1).
Reversibility of the Effects of Dex
Next, we tested the duration of the transcriptional and 
cellular effects of Dex in A549 cells. Withdrawal of Dex 
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TABLE 1.  GR Isoform Expression and p53 Status of Model NSCLC Cell Lines and Their Response to Dex
Cell Line p53 Status GRα Levela GRβ Levela
Effect of Dex on
TSb DHFRb S-Phase
A549 wt 1 0.008 Decrease Decrease Suppressed
H292 wt 1.2 0.005 Decrease Decrease Suppressed
H226 P72R 0.4 0.003 Decrease Decrease Suppressed
H460 wt 0.2 0.002 No effect No effect No effect
H358 Null 0.2 0.001 No effect No effect No effect
H1299 Null 0.2 0.001 No effect No effect No effect
ADLC-5M2 P72R 0.01 0.002 No effect No effect No effect
H1650 Wt 0.003 0.0002 No effect No effect No effect
aLevels of GRα and GRβ mRNAs are normalized values relative to the level of GRα in A549 cells. Percent error of the assay was < 5.
bTS and DHFR gene expression levels were determined by measuring mRNA by real-time reverse transcription polymerase chain reaction.
GR, glucocorticoid receptor; TS, thymidylate synthase; DHFR, dihydrofolate reductase.
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FIGURE 2.  Effect of Dex on cell-cycle phase distribution 
in A549 and H1299 cells. A549 cells (A) and H1299 cells 
(B) were plated at 20% confluence in media containing 
 charcoal-stripped serum for 24 hours for hormone depletion. 
Cells were then treated with either vehicle (ethanol) or Dex 
(100 nM) for 48 hours and harvested for flow cytometry analy-
sis. The experiments were repeated at least three times. Within 
each experiment, the percent error for replicate samples was < 
10%. The p values for Dex induced changes noted in the text 
were < 0.0001. Dex, dexamethasone.
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FIGURE 1.  Differential effects of Dex on the expression of genes involved in pemetrexed action in A549 versus H1299 cells. 
A549 cells (A and C) and H1299 cells (B and D) were plated at 20% confluence in media containing charcoal-stripped serum for 
24 hours for hormone depletion. Cells were then treated with either vehicle (ethanol) or Dex (100 nM) for 48 hours. Cells were 
harvested and total RNA extracted to measure mRNA levels by real-time RT-PCR (A and B). Whole cell lysates were also extracted 
from the cells to measure the protein levels of TS and DHFR by Western blot; GAPDH was used as the loading control (C and D). 
*p < 0.01. All the mRNA measurements were carried out using biological triplicate samples. Dex, dexamethasone; TS, thymi-
dylate synthase; DHFR, dihydrofolate reductase; AICARFT,  5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; 
GARFT, glycinamide ribonucleotide formyltransferase; RFC, reduced folate carrier; PCFT, proton coupled folate transporter; 
FPGS, folyl-polyglutamate synthase; TK1, thymidine kinase 1; RQ, relative quantification.
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restored the S-phase fraction to the original level (Fig. 3A); 
the reversal occurred within 24 hours of Dex withdrawal. 
Further, the S-phase recovery was accompanied by full res-
toration of TS and DHFR expression (Fig. 3B). These results 
demonstrate that the effects of Dex on the lung cancer cells 
are fully reversible.
Relationship of the Dex Effects to GR Status
The cell line models chosen for this study showed 
variable levels of GRα and GRβ determined by quantita-
tive RT-PCR (Table 1). Despite the fact that epithelial cells 
of the terminal bronchioles express GRβ, the expression of 
GRβ in the NSCLC cell lines was low compared with that of 
GRα (Table 1). The down-regulation of TS and DHFR or the 
suppression of S-phase by Dex occurred in A549 and H292 
cells that expressed relatively the highest GRα and in H226 
cells that expressed a moderate level of GRα. In contrast, the 
remaining cell lines that expressed lower levels of GRα were 
insensitive to Dex (Table 1). However, when GRα was trans-
duced in the low GRα-expressing H1299 cells (H1299-GRα 
cells in Fig. 4A), the Dex effect was restored, both in terms 
of down-regulation of TS and DHFR (Fig. 4B compared 
with Fig. 1B) and suppression of S-phase (Fig. 4C com-
pared with Fig. 2B). Therefore, variability in GRα expres-
sion level alone could be an important factor underlying the 
differences among NSCLC cells in terms of their ability to 
respond to Dex.
Relationship of the Dex Effects to p53 Status
The cell line models chosen also have variable p53 sta-
tus, including wt p53, mutant p53, and p53 deletions (Table 1). 
Ectopic GRα rescued the Dex effects in the p53-null H1299 
cells, indicating that in the presence of optimal GRα expres-
sion the cells may be responsive to Dex regardless of their 
p53 status (Fig. 4). However, H226 cells, which expressed 
the P72R mutant p53 were responsive to Dex although they 
expressed a moderate level of GRα in contrast to ADLC-5M2 
cells that also harbored the same p53 mutation but expressed 
much less GRα (Table 1). As the P72R mutant is known to 
share functional similarities with wt p53,21 it was of interest 
to test for a possible role of the mutant p53 in mediating the 
Dex effects in H226 cells. In H226 cells depleted of p53 by 
lentiviral transduction of p53shRNA (H226-p53KD cells, 
Fig. 5A), Dex still inhibited the expression of TS, DHFR, and 
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FIGURE 3.  Reversibility of Dex effects in A549 cells. A549 
cells were plated at 20% confluence in media containing 
charcoal-stripped serum for 24 hours for hormone deple-
tion. Cells were then treated with either vehicle (ethanol) or 
Dex (100 nM). After 48 hours, Dex was removed by washing 
the cells twice and replacing with fresh media. Cells were 
cultured for additional periods of 24 hours and 48 hours. 
Cells were harvested for flow cytometry analysis (A). The 
experiments were repeated at least three times. Within each 
experiment, the percent error for replicate samples was < 
10%. The p values for Dex induced changes noted in the text 
were < 0.0001. In parallel, cells were harvested for mRNA 
measurement by real-time reverse transcription polymerase 
chain reaction (B). *p < 0.01. All the mRNA measurements 
were carried out using biological triplicate samples. RQ, 
relative quantification; Dex, dexamethasone; TS, thymidylate 
synthase; DHFR, dihydrofolate reductase.
A B C
0
20
40
60
80
100
120
D
ist
ri
bu
tio
n 
in
 ce
ll 
cy
cl
e
H1299-GRαG2/MS
G1
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
G
R
α
m
R
N
A
 (R
Q)
*
0
0.2
0.4
0.6
0.8
1
1.2
Vehicle DexDHFR TS
m
R
N
A
 L
ev
el
 (R
Q)
H1299-GRαVehicle
Dex
*
*
FIGURE 4.  Effect of restoring GRα on responsiveness to Dex in H1299 cells. H1299-GRα cells were generated as described 
under Materials and Methods. RNA extracted from A549 cells, H1299 cells, and H1299-GRα cells was used to measure the 
relative mRNA levels for GRα (A). H1299-GRα cells were plated at 20% confluence in media containing  charcoal-stripped serum 
for 24 hours for hormone depletion. Cells were then treated with either vehicle (ethanol) or Dex (100 nM) for 48 hours. Cells 
were harvested for mRNA measurement by real-time reverse transcription polymerase chain reaction (B). *p < 0.01. In parallel, 
cells were harvested for cell-cycle analysis (C). The experiments were repeated at least three times. Within each experiment, the 
percent error for replicate samples was < 10 percent. The p values for Dex induced changes noted in the text were < 0.0001. 
All the mRNA measurements were carried out using biological triplicate samples. GR, glucocorticoid receptor; Dex, dexametha-
sone; RQ, relative quantification; TS, thymidylate synthase; DHFR, dihydrofolate reductase. 
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the additional S-phase marker TK1 (Fig. 5B); the effects of 
Dex in the transduced cells were comparable in degree with 
its effects in the parental H226 cells (Fig. 5C). In H226 cells, 
inhibition of the S-phase enzymes (Fig. 5C) as well as sup-
pression of the S-phase fraction of cells (data not shown) was 
moderate compared with that in A549 cells, likely reflecting 
the moderate expression level of GRα in H226 cells (Table 1). 
Taken together, the above results demonstrate that in nonsqua-
mous NSCLC cells, an optimal expression level of GRα sen-
sitizes cells to Dex independent of p53 status.
Effect of Dex on Cytotoxicity of Pemetrexed
As previously noted, the standard clinical regimen for 
pemetrexed treatment includes administration of Dex before, 
during, and after pemetrexed. The reversible Dex effects 
observed above implies that in Dex-sensitive nonsquamous 
NSCLC tumors, Dex could protect the tumor cells against 
the actions of pemetrexed for the duration of the drug treat-
ment by temporarily suppressing transition through S-phase. 
To test the effect of Dex on sensitivity to pemetrexed, A549 
and H1299 cells were pretreated with Dex and a pharma-
cologically relevant dose (5 μM) of pemetrexed was intro-
duced for a 24-hour period before withdrawing Dex. After the 
treatments, the effect of Dex on susceptibility of the cells to 
pemetrexed was examined both by the standard MTT growth 
assay and by monitoring clonogenic survival. In the absence 
of Dex treatment pemetrexed profoundly inhibited the growth 
(Fig. 6) and clonogenicity (Fig. 7) of both A549 and H1299 
cells, although when the cells were treated with Dex, there 
was a striking difference in the response of A549 cells versus 
that of H1299 cells. Dex had a protective effect on A549 cells 
against inhibition of growth and clonogenicity by pemetrexed 
(Figs. 6A and 7A, D); in contrast, Dex treatment did not affect 
the sensitivity of H1299 cells to pemetrexed (Figs. 6B and 7B, 
7E). However, Dex did protect against pemetrexed in H1299 
cells transduced with GRα (Fig. 7C, F). Therefore, in a clini-
cally relevant in vitro context, Dex-sensitive nonsquamous 
NSCLC cells are protected by Dex against growth inhibition 
by pemetrexed and this effect is dependent on the expression 
of an optimal level of GRα.
A B C
0
0.2
0.4
0.6
0.8
1
1.2
p5
3 
m
R
N
A
 (R
Q)
*
0
0.2
0.4
0.6
0.8
1
1.2
TS DHFR TK1
m
R
N
A
 L
ev
el
 (R
Q)
H226-p53KD
Vehicle
Dex
*
*
*
0
0.2
0.4
0.6
0.8
1
1.2
TS DHFR TK1
m
R
N
A
 L
ev
el
 (R
Q)
H226Vehicle
Dex
*
*
*
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FIGURE 6.  Differential effects of Dex on growth inhibition by pemetrexed in A549 versus H1299 cells. A549 cells (A) and H1299 
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DISCUSSION
Our studies of diverse nonsquamous NSCLC cell line 
models indicate that NSCLC cells are variable in their ability 
to respond to a pharmacological concentration of Dex. In the 
responsive cells, Dex slowed cell-cycle progression, specifi-
cally by suppressing progression into S phase. Concomitantly, 
Dex suppressed the expression of TS and DHFR, both of which 
are principal target enzymes of pemetrexed as well as critical 
S-phase enzymes. Among other determinants of pemetrexed 
cytotoxicity, Dex also decreased the expression of RFC and 
PCFT, the pharmacologically relevant principal membrane 
transporters of pemetrexed. The effects of Dex were reversible 
such that, after withdrawal of Dex, both the S-phase fraction 
of the cells as well as the levels of TS and DHFR were restored 
within 24 hours. As a predictable consequence of these revers-
ible effects of Dex, the cytotoxicity of pemetrexed was attenu-
ated by Dex when the cells were exposed to Dex before, 
concomitant with, and after pemetrexed treatment. Similar 
treatment with Dex did not influence pemetrexed cytotoxicity 
in cells in which it was unable to regulate the cell cycle or the 
expression of gene products involved in pemetrexed action.
Among the eight nonsquamous NSCLC model cell lines 
examined, the cells expressing a relatively high level of GRα 
were sensitive to Dex regardless of their p53 status. Further, the 
Dex effects were restored upon ectopic expression of GRα, in 
cells expressing relatively low endogenous GRα, even if they 
were p53 null. Cells that expressed a moderate level of GRα 
were moderately sensitive to Dex. In these cells, the studies 
also ruled out any contribution to Dex sensitivity in NSCLC 
cells attributable to the P72R mutant of p53, which report-
edly21 could be more effective in inducing stress response 
and apoptosis than wt p53 in different cell types. Although 
the p53 gene is a known target of glucocorticoids, p53 status 
is unlikely to have a major influence on response to Dex in 
nonsquamous NSCLC cells. Remarkably, despite the fact that 
epithelial cells of the terminal bronchioles, which may be pro-
genitors of lung adenocarcinoma express GRβ,14 expression 
of GRβ was low in all the NSCLC cell line models.
Patient response to pemetrexed has previously been 
shown to correlate negatively with tumor expression of TS 
and positively with tumor expression of folate receptor type α 
(FRα)22,23 but their relative expression is not a powerful inde-
pendent predictor of clinical response. Moreover, this associa-
tion cannot be attributed to a direct mechanistic link between 
drug sensitivity and the tumor levels of TS or FRα because of 
the following reasons: (1) The range of variability in tumor 
levels of TS determined by immunohistochemistry and related 
to pemetrexed treatment outcome is considerably narrower 
than that known to cause significant differences in cellular 
drug sensitivity at pharmacologic doses. For example, in the 
study by Christoph et al.23 patient response correlated with 
a mean H-score for TS expression of 187 ± 5 and a median 
score of 180 whereas the nonresponders had a mean score of 
201 ± 4 with a median of 210. In contrast, in vitro studies of 
lung cancer cell lines24 have shown that variability in IC50 
values for pemetrexed occurs over a much larger dynamic 
range of TS levels. Among various cell lines, the variability 
in TS levels that correlated with the variability in IC50 for 
pemetrexed occurred over a TS expression range of two orders 
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of magnitude. Further, within a single cell line, TS induction 
partially or fully contributing to pemetrexed resistance ranged 
from 2.5-fold to 20-fold.24 (2) FRα is not the pharmacologi-
cally relevant transporter of pemetrexed except in unusual sit-
uations when its expression level may be very high, combined 
with defects in RFC- or PCFT-mediated transport.5 However, 
as lower TS and higher FRα are known to be associated with 
reduced cell growth, they could reflect a smaller proportion 
of proliferating tumor cells. Therefore, it is quite likely that 
relative total TS and FRα values in the treatment-naive tumors 
may simply reflect the relative intrinsic growth rates of the 
tumors and hence relate to duration of survival after drug 
treatment. The present study advances a mechanism-based 
approach to understanding tumor responsiveness to peme-
trexed, based on the effects of Dex and offers a rational basis 
for predicting individual responses.
It is believed that despite the rapid systemic clearance 
of pemetrexed,10 cellular retention of pemetrexed by polyglu-
tamation confers a special advantage with effective outcomes 
through less frequent treatment cycles compared with other 
chemotherapy drugs. Indeed, both reduced FPGS expres-
sion and elevated γ-glutamyl hydrolase have been associated 
with pemetrexed resistance.25 However, clearance of Dex is 
relatively slow, with physiologically effective concentrations 
remaining in circulation for several days after Dex with-
drawal.26 This consideration, combined with the protective 
effects of Dex observed under the in vitro conditions used in 
the present study, strongly suggests that Dex-sensitive non-
squamous NSCLC tumors will be less responsive to standard 
pemetrexed treatment regimens. The findings in this study of 
the effects of Dex on NSCLC cell susceptibility to pemetrexed 
would likely extend to other S-phase acting chemotherapy 
drugs as well. However, in the clinical setting, Dex may have 
a lower impact on the action of platinum drugs that can form 
DNA adducts at any stage of the cell cycle, with the down-
stream cellular effects manifesting after the clearance of Dex. 
Our findings warrant clinical studies of nonsquamous NSCLC 
tumor responsiveness to pemetrexed in relation to Dex sensi-
tivity and GR status of the tumors.
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